Valuation: Cogent Biosciences, Inc.

Market Cap 6.77B 5.86B 5.49B 5.01B 9.42B 645B 9.56B 64.6B 25.25B 323B 25.4B 24.85B 1,077B P/E 2026 *
-17.4x
P/E 2027 * -40.5x
Enterprise Value 6.36B 5.51B 5.17B 4.71B 8.86B 607B 8.99B 60.75B 23.75B 304B 23.89B 23.37B 1,013B EV / Sales 2026 *
1,145x
EV / Sales 2027 * 21.6x
Free-Float
99.51%
Yield 2026 *
-
Yield 2027 * -
1 day+0.72%
1 week-7.78%
Current month+0.13%
1 month+0.28%
3 months+12.89%
6 months+6.15%
Current year+9.74%
1 week 37.81
Extreme 37.81
42.92
1 month 37.04
Extreme 37.04
43.39
Current year 30.87
Extreme 30.87
43.39
1 year 11.41
Extreme 11.41
43.73
3 years 3.67
Extreme 3.67
43.73
5 years 3.67
Extreme 3.67
43.73
10 years 3.67
Extreme 3.67
43.73
Manager TitleAgeSince
Chief Executive Officer 50 22/10/2020
Director of Finance/CFO 45 31/05/2018
Chief Tech/Sci/R&D Officer 52 05/04/2021
Director TitleAgeSince
Director/Board Member 68 31/01/2018
Director/Board Member 74 25/07/2019
Director/Board Member 59 25/07/2019
Date Insider Type Main position Quantity % Market Cap.
01/07/26 Free

Director

627 0.0004%
09/06/26 Free

Director

17,901 0.0105%
09/06/26 Free

Director

17,901 0.0105%
Change 5-day change 1-year change 3-year change Capi.($)
+0.72%-7.78%+237.49%+224.83% 6.77B
-0.73%+7.82%+73.81%+102.34% 70.1B
-0.03%+0.93%+38.13%+66.44% 54.93B
-0.22%+33.59%+8.43%+489.75% 28.89B
+0.04%+10.49%+48.44%+7.45% 23.9B
-0.06%+0.61%-16.45%-13.26% 23.3B
-1.37%+7.87%+251.71%+464.53% 18.41B
-0.42%+8.10%+41.15%-19.96% 18.77B
-0.57%+3.44%+25.60%+619.86% 16.1B
-1.85%-11.15%+32.75%+134.11% 12.48B
Average -0.45%+6.76%+74.11%+207.61% 27.36B
Weighted average by Cap. -0.44%+9.00%+58.91%+168.80%

Financials

2026 *2027 *
Net sales 5.56M 4.82M 4.51M 4.12M 7.74M 530M 7.86M 53.07M 20.75M 265M 20.87M 20.42M 885M 309M 268M 251M 229M 430M 29.49B 437M 2.95B 1.15B 14.77B 1.16B 1.14B 49.24B
Net income -408M -354M -331M -302M -568M -38.92B -577M -3.9B -1.52B -19.49B -1.53B -1.5B -64.99B -177M -153M -143M -131M -246M -16.84B -250M -1.69B -659M -8.43B -663M -649M -28.12B
Net Debt -403M -349M -327M -298M -560M -38.4B -569M -3.84B -1.5B -19.23B -1.51B -1.48B -64.12B -77.95M -67.54M -63.28M -57.72M -109M -7.44B -110M -744M -291M -3.72B -293M -286M -12.41B
Logo Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a clinical-stage biotechnology company. It is focused on developing precision therapies for genetically defined diseases. Its approach is to design rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its advanced program is bezuclastinib, also known as CGT9486, a highly selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis (SM), a serious and rare disease caused by unchecked proliferation of mast cells. The Company has on-going Phase I studies of its CNS-penetrant, selective mutant ErbB2 inhibitor and its potential best-in-class, wild-type-sparing, PI3Ka inhibitor. In addition, the Company’s research team is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases targeting mutations in KRAS and JAK2.
Employees
258
Date Price Change Volume
12/08/26 US$38.98 +0.72% 2,977,684
11/08/26 US$38.70 -6.81% 2,781,611
10/08/26 US$41.53 -2.03% 1,616,939
07/08/26 US$42.39 +1.41% 1,855,798
06/08/26 US$41.80 -1.11% 1,043,363
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
38.98USD
Average target price
53.83USD
Spread / Average Target
+38.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. COGT Stock